Related references
Note: Only part of the references are listed.A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC)
Arthur Caplan et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2019)
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
Amy E. McKee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Overview of FDA's Expanded Access Program for Investigational Drugs
Jonathan P. Jarow et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2017)
The Ethical Challenges of Compassionate Use
Arthur L. Caplan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label
Stacy E. Croteau et al.
PEDIATRIC BLOOD & CANCER (2016)
Right-to-try laws and individual patient compassionate use of experimental oncology medications: A call for improved provider-patient communication
Michael Hoerger
DEATH STUDIES (2016)
Clinical trials in children
Pathma D. Joseph et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Should patients in need be given access to experimental drugs?
Arthur L. Caplan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam
Julie A. Jacob
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Principles and Challenges in Access to Experimental Medicines
Michael Rosenblatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs
Tamy Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Expanded access programmes: patient interests versus clinical trial integrity
Paul Lorigan et al.
LANCET ONCOLOGY (2015)
Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs
Jonathan J. Darrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dilemmas in the compassionate supply of investigational cancer drugs
J. R. R. Lewis et al.
INTERNAL MEDICINE JOURNAL (2014)
Food and Drug Administration Responds to Pressure for Expanded Drug Access
Vicki Brower
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
New Regulatory Paradigms for Innovative Drugs to Treat Pediatric Diseases
Thomas J. Hwang et al.
JAMA PEDIATRICS (2014)
Clinicians' Expectations for Gene-Driven Cancer Therapy
Antti Jekunen
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2014)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Ethical Issues in Neonatal and Pediatric Clinical Trials
Naomi Laventhal et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2012)
COMPASSIONATE USE a story of ethics and science in the development of a new drug
William C. Buhles
PERSPECTIVES IN BIOLOGY AND MEDICINE (2011)
Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
Wim Pinxten et al.
JOURNAL OF MEDICAL ETHICS (2010)
Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
Manik Chahal
JOURNAL OF MEDICAL ETHICS (2010)
Access to Experimental Drugs for Terminally Ill Patients
Benjamin P. Falit et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Phase I trials in pediatric oncology: Perceptions of pediatricians from the United Kingdom Children's Cancer Study Group and the Pediatric Oncology Group
EJ Estlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
